Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-TKI plus S-1 versus EGFR-TKI alone as first-line therapy for EGFR-mutant advanced non-small cell lung cancer
ChiCTR1900020520Phase 2Recruiting
- Sponsor
- Liuzhou People's Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tegafur in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Liuzhou People's Hospital. Primary endpoint: progression-free survival. Started Jan 2019; status: recruiting.
02
Drugs
tegafur
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900020520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020520.